- eXmoor Pharma and the Royal Free London NHS Foundation Trust’s CVIC have entered a collaboration to connect early and later-phase cell and gene therapy manufacturing capabilities in the UK.
- The partnership aims to streamline translational processes, align quality systems, and support innovators from early research through to commercial readiness.
eXmoor Pharma and the Royal Free London NHS Foundation Trust, through its Cell and Vector Innovation Centre (CVIC), have formed a strategic collaboration to strengthen the UK’s cell and gene therapy development and manufacturing ecosystem. The agreement links CVIC’s early-phase clinical manufacturing expertise with eXmoor’s later-phase capabilities and its planned progression toward a commercial manufacturing licence.
The partnership aims to build an integrated translational pathway that reduces complexity and supports academic, clinical and commercial innovators as they progress from proof of concept to first-in-human studies and eventual commercial delivery. By aligning technology transfer processes, regulatory expertise and quality systems, the collaboration seeks to create smoother transitions between development stages.
Joint areas of work will include harmonised technology transfer protocols, shared regulatory strategy, Qualified Person responsibilities and collaborative process development. The organisations will also support knowledge exchange and staff training across both teams to strengthen capability within the UK.
“This collaboration is a powerful example of how the UK’s strength in early research can be matched with long-term manufacturing foresight.”
Angela Osborne, Founder and Executive Chair of eXmoor Pharma
Owen Bain, Director of CVIC, stated that the partnership will connect NHS early-phase experience with eXmoor’s development and commercial manufacturing expertise.
The organisations noted that the model is intended to provide clarity to early-stage innovators on long-term feasibility while demonstrating robust UK-based manufacturing options to domestic and international stakeholders.
